Tempus AI (NASDAQ:TEM) Shares Gap Up - Time to Buy?

Tempus AI logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Tempus AI shares opened higher but reversed: The stock opened at $67.12 versus a prior close of $64.76, then traded at $64.255, down about 3.8% from the previous close.
  • Quarterly results beat expectations: Tempus AI reported adjusted earnings of $0.07 per share, versus an expected loss of $0.09, and revenue of $411.54 million, up 23.1% year over year.
  • Analyst views remain mixed: Cantor Fitzgerald raised its price target to $92 and BTIG to $100, but the consensus rating is “Hold” with an average target of $79.37. Insiders also sold about $74.2 million in shares over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $64.76, but opened at $67.12. Tempus AI shares last traded at $64.2550, with a volume of 931,207 shares.

Analyst Upgrades and Downgrades

Several research firms have commented on TEM. Raymond James Financial set a $80.00 price objective on Tempus AI in a research note on Wednesday, September 2nd. Cantor Fitzgerald upped their target price on Tempus AI from $80.00 to $92.00 and gave the company an "overweight" rating in a report on Tuesday, November 3rd. Wall Street Zen raised shares of Tempus AI from a "sell" rating to a "hold" rating in a research note on Saturday, July 25th. UBS Group initiated coverage on Tempus AI in a report on Wednesday, September 9th. They issued a "neutral" rating and a $70.00 target price on the stock. Finally, BTIG Research boosted their price target on Tempus AI from $80.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, November 3rd. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of "Hold" and a consensus price target of $79.37.

Check Out Our Latest Stock Report on TEM

Tempus AI Stock Down 3.8%

The firm has a market cap of $11.37 billion, a P/E ratio of -58.53 and a beta of 3.61. The firm's 50-day moving average price is $72.84 and its 200 day moving average price is $57.54. The company has a quick ratio of 2.48, a current ratio of 2.61 and a debt-to-equity ratio of 2.70.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.16. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The company's quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.46) earnings per share. As a group, research analysts expect that Tempus AI, Inc. will post -1.20 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Eric Lefkofsky sold 250,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total value of $19,367,500.00. Following the completion of the transaction, the chief executive officer owned 100,000 shares of the company's stock, valued at approximately $7,747,000. This trade represents a 71.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan Bartolucci sold 7,062 shares of the firm's stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the sale, the chief accounting officer directly owned 60,804 shares of the company's stock, valued at $4,560,300. This trade represents a 10.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,012,689 shares of company stock valued at $74,249,653. Company insiders own 24.26% of the company's stock.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of the business. Ausdal Financial Partners Inc. bought a new position in shares of Tempus AI in the 3rd quarter valued at about $218,000. Lighthouse Investment Partners LLC grew its position in Tempus AI by 72.3% during the third quarter. Lighthouse Investment Partners LLC now owns 12,942 shares of the company's stock worth $1,060,000 after buying an additional 5,429 shares in the last quarter. Waterloo Capital L.P. increased its position in shares of Tempus AI by 10.2% in the third quarter. Waterloo Capital L.P. now owns 7,781 shares of the company's stock worth $637,000 after purchasing an additional 720 shares during the period. Dearborn Partners LLC bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $281,000. Finally, Entropy Technologies LP raised its stake in Tempus AI by 36.4% during the third quarter. Entropy Technologies LP now owns 147,040 shares of the company's stock worth $12,043,000 after acquiring an additional 39,262 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines